Bioglass® is a bioactive, resorbable ceramic particle that was developed to assure binding to living tissues. Bioglass® is currently employed to fill osseus defects in oral surgery, and it possesses both unique anti-inflammatory and antimicrobial properties. In an effort to determine whether Bioglass® may be useful as an adjunct anti-inflammatory device in local inflammatory processes, we examined whether exposure of the peritoneal cavity to Bioglass® would induce a pro-or anti-inflammatory response, and then modulate a subsequent proinflammatory response to endotoxin. Three-to fifty-milligram doses of 5 μm Bioglass® were administered intraperitoneally in C57BL/6 mice. Total leukocyte, myeloperoxidase, and cytokine levels in the peritoneal wash fluid were determined. In addition, the peritoneal cavity was pre-exposed to Bioglass®, and was then subjected to a subsequent endotoxin administration. All doses of Bioglass® were found to induce a significant peritoneal IL-6 response; however, Bioglass® did not induce a TNF-α, IL-1α, IL-10, or a white cell recruitment into the peritoneal lavage fluid. Pretreatment of the peritoneal cavity with Bioglass® produced a transient reduction in the proinflammatory response to endotoxin. We conclude that exposure to Bioglass® produces an IL-6 response without concurrent expression of TNF-α or IL-1α. Bioglass® appears to transiently suppress the inflammatory response to endotoxin, possibly through the early induction of IL-6. These findings suggest that Bioglass® may offer a unique approach in modifying the inflammatory response in local tissue compartments.
ASJC Scopus subject areas
- Emergency Medicine
- Critical Care and Intensive Care Medicine